Jane Street’s Alzamend Neuro ALZN Stock Holding History

Jane Street’s Portfolio ALZN Stock Details ALZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-8	Closed	-$14K	–	9572
2022 Q1	$14K	Sell	8 -32	-80%	-$60.1K	﹤0.01%	10017
2021 Q4	$102K	Buy	+40	New	+$124K	﹤0.01%	9240

Other funds holding ALZN

Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

RFG Advisory Birmingham, Alabama $6.4B AUM 19.93% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

IIC

Integrated Investment Consultants Bloomfield Hills, Michigan $471M AUM 20.31% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jane Street's ALZN Position: Q2 2023 in Review

Jane Street sold out of Alzamend Neuro (ALZN) in Q2 2023, closing a stake of 9 shares — an estimated $5.1K sold.

Jane Street first reported a position in ALZN in Q2 2021 and held it in 6 quarters. The position peaked at $1.17M in Q2 2021. 20 funds tracked by Wall St. Rank hold ALZN as of Q2 2023.

Jane Street reported no remaining Alzamend Neuro position as of Q2 2023 after selling out during the quarter.
Jane Street sold 9 Alzamend Neuro shares in Q2 2023, an estimated $5.1K.
Jane Street first reported a position in Alzamend Neuro in Q2 2021 and held it in 6 quarters.
Jane Street's Alzamend Neuro position peaked at $1.17M in Q2 2021.
20 funds tracked by Wall St. Rank held Alzamend Neuro as of Q2 2023.

Based on Jane Street's 13F filing for Q2 2023, filed 14 Aug 2023.